University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Symposium 2014

Targeting RAS Now for Future Cancer Therapy

June 19th (9:00 am - 5:30 pm)
June 20th (8:00 am - 12:45 pm)

Byers Auditorium, 600 16th Street, Mission Bay

This event has passed.  Thank you to all who attended or viewed online.


Read more about RAS research at UCSF in "Targeting Key Driver of Cancer," 6/18/2014

The 2014 Helen Diller Family Comprehensive Cancer Center Symposium, “Targeting RAS Now for Future Cancer Therapy”, will be held Thursday, June 19th and Friday, June 20th, 2014 at the University of California, San Francisco Mission Bay campus.

There will be five scientific sessions that will span the gamut of RAS biology and biochemistry in relation to normal and abnormal development and relevance to cancer initiation, progression and therapy. The scientific sessions will be open to academic and industry colleagues in the Bay Area. 

Agenda     Sponsors    Contact

Thursday, June 19th
8:30 AM Continental Breakfast
9:00 AM - 9:30 AM Welcome & Introduction
9:30 AM - 11:45 AM

Session 1: Direct Attack on the Ras Protein   (Chair: Laura van 't Veer, PhD)

K.ShokatA small molecule inhibitor of K-Ras G12C
Kevan Shokat, PhD
Professor and Chair of Cellular and Molecular Pharmacology, UCSF

S.FesikTargeting Ras by Activating SOS-Mediated Nucleotide Exchange
Stephen W. Fesik, PhD
Professor of Biochemistry, Pharmacology, and Chemistry, Vanderbilt-Ingram Cancer Center


C.MattosConsidering the nuances of Ras conformational states and distinct effects of G12, G13 and Q61 mutations
Carla Mattos, PhD
Professor of Chemistry, Northeastern University


11:45 AM - 12:45 PM Lunch
12:45 PM - 3:00 PM

Session 2: Disrupting Ras Signaling in the Membrane   (Chair: Jeroen Roose, PhD)

J.FaginMerlin, Hippo and RAS-induced tumorigenesis
James Fagin, MD
Chief of Endocrinology Service, Memorial Sloan-Kettering Cancer Center

H.WaldmanSmall molecule modulation of KRas localization and signalling
Herbert Waldmann, PhD
Professor of Chemistry, Max Planck Institute of Molecular Physiology

D.Bar-SaghiFunction-based targeting of oncogenic Ras
Dafna Bar-Sagi, PhD
Professor of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center

3:00 PM - 3:15 PM Break
3:15 PM - 5:30 PM

Session 3: Targets Downstream of KRAS  (Chair: W. Michael Korn, MD)

D. MorrisonRegulation of Raf signaling in normal and disease states
Deborah Morrison, PhD
Chief, Laboratory of Cell Development and Signaling, NCI Center for Cancer Research

J.DownwardApproaches to indirect targeting of RAS in tumors: oncogene addiction and non-oncogene addiction
Julian Downward, PhD
Professor, Cancer Research UK

M.McMahonCooperative regulation of tumor maintenance by the RAS-activated ERK MAP kinase and PI3'-kinase pathways
Martin McMahon, PhD
Professor, Helen Diller Family Comprehensive Cancer Center, UCSF

5:45 PM Cocktail Reception
Friday, June 20th
7:30 AM Continental Breakfast
8:00 AM - 10:15 AM

Session 4: Ras and NF1 in Human Cancer   (Chair: Ben Braun, MD, PhD)

K.ShannonIn Vivo Models of Hematologic Cancers Driven by Hyperactive Ras
Kevin Shannon, MD
Professor of Pediatrics, UCSF

E.JacksonInvestigating Intratumoral Heterogeneity in K-ras Driven Cancer Models
Erica Jackson, PhD
Scientist, Genentech, Inc.

E.CollissonNF1 Loss In Non Small Cell Lung Cancer
Eric Collisson, MD
Assistant Professor of Medicine, UCSF

10:15 AM - 10:30 AM Break
10:30 AM - 12:45 PM

Session 5: Novel Properties of Ras  (Chair: Alan Ashworth, PhD)

X.NanMolecules go marching two by two: Ras, Raf, and beyond
Xiaolin Nan, PhD
Assistant Professor of Biomedical Engineering, Oregon Health & Science University

C.BurdDeciphering codon-specific RAS oncogenicity in mouse models of melanoma
Christin Burd, PhD
Assistant Professor of Molecular Genetics, The Ohio State University

F.McCormickNew ways of targeting K-RAS
Frank McCormick, PhD, FRS, DSc (Hon)
Professor Emeritus, Helen Diller Family Comprehensive Cancer Center, UCSF

12:45 PM Adjourn





Contact Jordan Brainerd at for more information.


Image: Structure of drug-bound KRAS. Image courtesy of Jonathan Ostrem (Shokat Lab, UCSF)